نتایج جستجو برای: cell chronic lymphocytic leukemia b

تعداد نتایج: 2734448  

Journal: :Haematologica 2012
Preetesh Jain Mohammad Javdan Franziska K Feger Pui Yan Chiu Cristina Sison Rajendra N Damle Tawfiqul A Bhuiya Filiz Sen Lynne V Abruzzo Jan A Burger Andreas Rosenwald Steven L Allen Jonathan E Kolitz Kanti R Rai Nicholas Chiorazzi Barbara Sherry

BACKGROUND The levels and clinical relevance of Th17 cells and other interleukin-17-producing cells have not been analyzed in chronic lymphocytic leukemia. The objective of this study was to quantify blood and tissue levels of Th17 and other interleukin-17-producing cells in patients with this disease and correlate blood levels with clinical outcome. DESIGN AND METHODS Intracellular interleuk...

Journal: :Rheumatology 2005
A Angel-Moreno Maroto E Martínez-Quintana L Suárez-Castellano J-L Pérez-Arellano

1. Lischner M, Prokocimer M, Zolberg A, Shaklai M. Autoimmunity in chronic lymphocytic leukaemia. Postgrad Med J 1988;64:590–2. 2. Salvi A, Balestrier GP, Spandrio S, Franceschini R, Maroccolo M, Giustina G. Polymyositis associated with chronic lymphocytic leukemia. Clin Exp Rheumatol 1991;9:209–10. 3. Cherin P, Piette JC, Herson S, Raguin G, Godeau P. Polymyositis associated with chronic lymph...

2017
Lucas A. Heldt Manica Philip R. Cohen

Chronic lymphocytic leukemia is a lymphoproliferative disorder characterized by a gradual accumulation of neoplastic B-lymphocytes. Ibrutinib is a novel therapy for chronic lymphocytic leukemia. Ibrutinib therapy has been associated with nail plate abnormalities. Other common cutaneous adverse events caused by ibrutinib appear to be bruising, hair changes, pruritus, and rashes. We describe the ...

Journal: :Memo – Magazine of European Medical Oncology 2021

Summary The treatment landscape of chronic lymphocytic leukemia (CLL) has shifted from chemotherapy-based approaches to targeted agents in the last decade. However, evolving drug resistance and accumulating toxicity remain challenges that still limit patients’ clinical outcomes. Furthermore, currently licensed such as inhibitors Bruton’s tyrosine kinase (BTK) anti-apoptotic protein B‑cell lymph...

Journal: :Current topics in microbiology and immunology 1983
K Kinoshita S Ikeda Y Yamada T Amagasaki S Momita K Toriya M Ichimaru S Kamihira

We screened serum samples from patients with various hematological disorders and healthy individuals for the presence of adult T-cell leukemia/lymphoma associated antigen (anti-ATLA) antibodies. These antibodies were detected not only in all patients with ATL but frequently in those diagnosed as T-cell malignant lymphoma or T-cell chronic lymphocytic leukemia; the positivity rate of anti-ATLA a...

Journal: :Blood 2012
Jorge Cortes

It is unclear if this is a direct effect or mediated by kinase inhibition. Sphingolipids are also known as mediators of mitochondrial apopto-sis. Consistent with the antiapoptotic effect of glucosylceramide, BCR stimulation reduced the effect of the mitochondria-targeting drug ABT-737. Concomitant treatment with low doses of the kinase (and apparently UGCG) inhibitors GS-1101 and ibrutinib rest...

Journal: :Cancer research 1995
M C Devilder S François C Bosic A Moreau M P Mellerin D Le Paslier R Bataille J P Moisan

The presence of an unidentified tumor suppressor gene on the long arm of chromosome 13 which could be involved in the development of B cell chronic lymphocytic leukemia has been suspected because of frequent deletions of the locus D13S25 which lies 1.6 cM telomeric to the retinoblastoma gene. In order to accurately map this gene, cells from 25 B cell chronic lymphocytic leukemia tumors have bee...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید